Evidence map›Paper›PMID 34257557›Full record

ArticlePathology oncology research : POR2021

Development of a Novel Prognostic Signature Based on Antigen Processing and Presentation in Patients with Breast Cancer.

Aoshuang Qi, Mingyi Ju, Yinfeng Liu, Jia Bi, Qian Wei, Miao He, Minjie Wei, Lin Zhao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathology oncology research : POR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Aoshuang QiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
Mingyi JuDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
Yinfeng LiuDepartment of Breast Surgery, The First Hospital of Qinhuangdao, Qinhuangdao, China.
Jia BiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
Qian WeiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
Miao HeDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
Minjie WeiDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
Lin ZhaoDepartment of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China.
China Medical University · CNFirst Hospital of Qinhuangdao · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antigen PresentationBiomarkers, TumorBreast NeoplasmsEndoplasmic Reticulum Chaperone BiPFemaleFollow-Up StudiesHistocompatibility Antigens Class IHumansMiddle AgedPrognosisProteasome Endopeptidase ComplexSurvival RateTranscriptomeBiomarkers, TumorEndoplasmic Reticulum Chaperone BiPHistocompatibility Antigens Class IHLA-F antigensHSPA5 protein, humanProteasome Endopeptidase ComplexPSME2 protein, humanantigen processing and presentationbreast cancercell biologyprognosticsurvival

Identifiers

PMID34257557
PMCPMC8262234
OpenAlexW3150385600

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.